3 Contract Pharmaceuticals Maker, Global IT Services Company and Air Conditioning Company Stocks With a Strong Future Roadmap: Innova Captab, Infosys and Blue Star
- November 12, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Innova Captab, Infosys and Blue Star: ROE of 12.9% to 31.0% and FY22 to FY26 revenue CAGR of 10.2% to 19.6%. Prices as of 11 Nov 2026.
Quick Answer
The three drug maker, IT services and cooling stocks to watch are Innova Captab, Infosys and Blue Star. Their return on equity ranges from 12.9% to 31.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.2% to 19.6%. Infosys has the highest return on equity at 31.0%, while Blue Star has the fastest revenue growth at 19.6% a year. Prices are based on the 11 November 2026 close, and this article is educational, not investment advice.
Drug maker, IT services and cooling stocks let investors follow companies that serve a growing part of the Indian economy. Innova Captab, Infosys and Blue Star cover a contract pharmaceuticals maker, a global IT services company and an air conditioning company.
This list covers three drug maker, IT services and cooling stocks with complete current figures: Innova Captab, Infosys and Blue Star. Every figure comes from the latest reported financials and the 11 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Drug Maker, IT Services and Cooling Stocks?
Drug maker, IT services and cooling stocks are listed companies that make tablets, capsules and injectables for domestic and global drug firms, provide IT, cloud and consulting services to global clients, and make air conditioners, commercial cooling and refrigeration systems. Their earnings depend on prescription demand, client technology budgets and summer and commercial cooling demand.
Drug Maker, IT Services and Cooling Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Innova Captab | 1,092 | 5,736 | 37.2 | 36.0 | 12.9 | 0.32 |
| Infosys | 1,155 | 468,528 | 15.4 | 17.6 | 31.0 | 0.09 |
| Blue Star | 1,563.8 | 32,243 | 63.3 | 43.1 | 15.4 | 0.24 |
On valuation, Infosys trades at a P/E below the industry P/E, while Innova Captab and Blue Star trade above it, which reflects the growth the market already expects. Readers comparing drug maker, IT services and cooling stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Drug Maker, IT Services and Cooling Stocks Have a Strong Roadmap in India?
Drug maker, IT services and cooling stocks have a strong roadmap in India because steady outsourcing of drug making, wider enterprise adoption of digital services and rising use of air conditioning keep widening the market for these companies.
- Contract pharma. Global drug firms outsource production.
- IT services. Clients invest in cloud and digital work.
- Cooling. Homes and offices add air conditioning.
Why Innova Captab Features Among These Drug Maker, IT Services and Cooling Stocks
Among the drug maker, IT services and cooling stocks on this list, Innova Captab is a Himachal Pradesh-based pharmaceutical company that makes formulations for other pharma companies, manufactures its own branded generics and supplies active ingredients.
Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%.
In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0.
Roadmap: The company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.
What to watch: Watch the growth in the branded business and the utilisation of expanded capacity.
Why Infosys Features Among These Drug Maker, IT Services and Cooling Stocks
Among the contract pharma, software and room cooling shares on this list, Infosys is a leading Indian technology services company that provides digital, cloud, data and consulting services to global enterprises across banking, retail, energy and other industries.
Revenue rose from Rs 123,936 crore in FY22 to Rs 182,972 crore in FY26, a compound annual growth rate of 10.2%. Net profit grew from Rs 22,146 crore in FY22 to Rs 29,474 crore in FY26, which works out to a compound annual growth rate of 7.4%.
The company has a return on equity of 31.0%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 468,528 crore. The stock trades at a P/E of 15.4, below the industry P/E of 17.6.
Roadmap: The company is investing in artificial intelligence and cloud services, which are becoming central to client budgets. Large deal wins and strong client relationships support steady growth.
What to watch: Track large deal wins, margin trends and client demand for artificial intelligence services.
Why Blue Star Features Among These Drug Maker, IT Services and Cooling Stocks
Among the three companies on this list, Blue Star is an air conditioning and commercial refrigeration company that sells room air conditioners, cooling products and electro-mechanical projects across India.
The company has a return on equity of 15.4%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 32,243 crore. The stock trades at a P/E of 63.3, above the industry P/E of 43.1.
Revenue rose from Rs 6,100 crore in FY22 to Rs 12,464 crore in FY26, a compound annual growth rate of 19.6%. Net profit grew from Rs 168 crore in FY22 to Rs 527 crore in FY26, which works out to a compound annual growth rate of 33.1%. In the June 2026 quarter, revenue grew 13.4% year on year to Rs 3,399 crore.
Roadmap: The company benefits from rising air conditioner penetration, growth in commercial buildings and expansion of cold chain. A wide service network and trusted brand support market share.
What to watch: Track room air conditioner volumes, commercial cooling orders and project execution.
Innova Captab vs Infosys vs Blue Star on Key Financials
The table below sets the three drug maker, IT services and cooling stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Innova Captab | 803 | 1,637 | 19.5% | 141 | 8.6% |
| Infosys | 123,936 | 182,972 | 10.2% | 29,474 | 16.1% |
| Blue Star | 6,100 | 12,464 | 19.6% | 527 | 4.2% |
Infosys posts the highest return on equity in this group at 31.0%. Infosys has the largest FY26 revenue at Rs 182,972 crore, and Blue Star shows the fastest revenue growth with a 19.6% compound annual rate. A useful habit with drug maker, IT services and cooling stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Drug Maker, IT Services and Cooling Stocks
Every theme carries risks that deserve a check before any decision. For these drug maker, IT services and cooling stocks, the main points are: Long-term contract pharma, software and room cooling shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Client spending. Technology budgets can vary with global conditions.
- Demand cycles. Sales can vary with seasons and rates.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter drug maker, IT services and cooling stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Drug Maker, IT Services and Cooling Stocks
Drug maker, IT services and cooling stocks reward investors who follow demand trends, order books and margins together. Innova Captab, Infosys and Blue Star each have a clear plan to grow. Based on the 11 November 2026 close, Innova Captab trades at Rs 1,092, Infosys at Rs 1,155 and Blue Star at Rs 1,563.8.
Download the Univest iOS App or Univest Android App to track drug maker, IT services and cooling stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are drug maker, IT services and cooling stocks?
Ans. Drug maker, IT services and cooling stocks are listed companies that make tablets, capsules and injectables for domestic and global drug firms, provide IT, cloud and consulting services to global clients, and make air conditioners, commercial cooling and refrigeration systems. Their earnings depend on prescription demand, client technology budgets and summer and commercial cooling demand. This list looks at three of them, Innova Captab, Infosys and Blue Star, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.
Which drug maker, IT services and cooling stocks are covered in this list?
Ans. This list covers Innova Captab, Infosys and Blue Star. Based on the 11 November 2026 close, Innova Captab traded at Rs 1,092, Infosys at Rs 1,155 and Blue Star at Rs 1,563.8. Their return on equity ranges from 12.9% to 31.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.2% to 19.6%.
Why do drug maker, IT services and cooling stocks have a strong future roadmap in India?
Ans. Drug maker, IT services and cooling stocks have a strong roadmap in India because steady outsourcing of drug making, wider enterprise adoption of digital services and rising use of air conditioning keep widening the market for these companies. The main drivers are as follows. Contract pharma. Global drug firms outsource production. IT services. Clients invest in cloud and digital work. Cooling. Homes and offices add air conditioning. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Innova Captab performed financially?
Ans. Revenue rose from Rs 803 crore in FY22 to Rs 1,637 crore in FY26, a compound annual growth rate of 19.5%. Net profit grew from Rs 64.0 crore in FY22 to Rs 141 crore in FY26, which works out to a compound annual growth rate of 21.8%. In the June 2026 quarter, revenue grew 32.8% year on year to Rs 473 crore, while net profit rose 42.3% to Rs 44.1 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.32 and a market capitalisation of Rs 5,736 crore. The stock trades at a P/E of 37.2, above the industry P/E of 36.0. Looking ahead, the company combines contract manufacturing with its own branded generics business, which lets it capture more of the value chain. It has also been expanding capacity and widening its customer base.
How has Infosys performed financially?
Ans. Revenue rose from Rs 123,936 crore in FY22 to Rs 182,972 crore in FY26, a compound annual growth rate of 10.2%. Net profit grew from Rs 22,146 crore in FY22 to Rs 29,474 crore in FY26, which works out to a compound annual growth rate of 7.4%. The company has a return on equity of 31.0%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 468,528 crore. The stock trades at a P/E of 15.4, below the industry P/E of 17.6. Looking ahead, the company is investing in artificial intelligence and cloud services, which are becoming central to client budgets. Large deal wins and strong client relationships support steady growth.
How has Blue Star performed financially?
Ans. Revenue rose from Rs 6,100 crore in FY22 to Rs 12,464 crore in FY26, a compound annual growth rate of 19.6%. Net profit grew from Rs 168 crore in FY22 to Rs 527 crore in FY26, which works out to a compound annual growth rate of 33.1%. In the June 2026 quarter, revenue grew 13.4% year on year to Rs 3,399 crore. The company has a return on equity of 15.4%, a debt to equity ratio of 0.24 and a market capitalisation of Rs 32,243 crore. The stock trades at a P/E of 63.3, above the industry P/E of 43.1. Looking ahead, the company benefits from rising air conditioner penetration, growth in commercial buildings and expansion of cold chain. A wide service network and trusted brand support market share.
What risks should investors check before buying drug maker, IT services and cooling stocks?
Ans. Investors should check a few risks before buying drug maker, IT services and cooling stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Client spending. Technology budgets can vary with global conditions. Demand cycles. Sales can vary with seasons and rates. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of drug maker, IT services and cooling stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
